Enable Injections

We will be attending @PharmapackEu from Jan 21 -22 in Paris and are looking forward to connecting with industry partners. If you're interested in learning more about the enFuse® system, connect with Matthew Huddleston CCO & EVP to schedule a time to meet. #Pharmapack #enFuse

Enable Injections announces $30 million investment from @sanofi to accelerate Enable’s manufacturing capabilities to further strengthen ability to meet growing demand for the enFuse® On-Body Delivery System. Learn more here: bit.ly/3N8wuJJ #enFuse #drugdelivery

Wishing you a happy and healthy holiday season from all of us at Enable Injections. We’re grateful for such a meaningful year and excited for what is ahead. #happyholidays #2025

We’re excited to announce the EMPAVELI® Injector, based on the enFuse® On-Body Delivery System, has received marketing authorization from the Saudi Food and Drug Authority, marking another global regulatory approval for our technology! Read more here: bit.ly/4pEm42R

We’re grateful for all our supporters in our mission to improve the patient experience, and especially thankful for our dedicated team members for their hard work and commitment this year and every year. Happy Thanksgiving from our Enable Injections family to yours!

A recent publication in @AAPSComms explores the challenges and opportunities in developing high-concentration subcutaneous biologic formulations: lnkd.in/egHs3MZm At Enable, we’re bridging the gap between formulation science and delivery innovation. #drugdelivery

Thank you to everyone who visited our booth at the PDA Universe of Pre-Filled Syringes and Injection Devices Conference 2025! Our team enjoyed meeting you and demonstrating the innovative enFuse® On-Body Delivery System. Contact us to learn more: lnkd.in/eKacC7Xp

We are excited to announce a new partnership with Incyte to develop and commercialize specific assets in Incyte’s portfolio with the enFuse® On-Body Delivery System! Learn more here: bit.ly/3Wp7zmA

Between the pipeline of talent, economic incentives, and the wide network of support across the #lifesciences ecosystem, Enable Injections is proud to call #Cincinnati home! Read more about this growing industry in the region from the @BusinessCourier: lnkd.in/gkxDt6NU

#KidneyWk, hosted by the American Society of Nephrology (ASN) is only a month away! If you’re attending, stop by Booth 202 for a demonstration of our enFuse system or contact us to set up a meeting: lnkd.in/eKacC7Xp #DrugDelivery #largevolume #enFuse

#PODD2025 is only a month away! If you’re attending, stop by Booth 701 for a demonstration of our enFuse system or contact us to set up a meeting: lnkd.in/eKacC7Xp #DrugDelivery #largevolume #subcutaneousdelivery #enFuse

Be sure to catch our session “Addressing Large-Volume Subcutaneous Delivery Challenges with enFuse: A Patient- and Provider-Centric Solution” at PDA Universe of Pre-Filled Syringes and Injection Devices Conference 2025, Oct 21. #PDA #drugdelivery #enFuse

Are you ready to make an impact and create meaningful change in a growing company and in the lives of patients? Check out the opportunity here: lnkd.in/gEWjAZP2 ​ #Hiring #enFuse

The future of patient care lies not only in the drugs we discover, but in how we deliver them. The latest edition of @ONdrugDelivery is here, focusing on wearable injectors and featuring the innovative enFuse drug delivery system! Read the full article: bit.ly/3K3EMB8

We’re excited to announce the enFuse System has been approved by Brazilian Health Regulatory Agency (Agencia Nacional de Vigilancia Sanitaria or ANVISA)! . Read the full announcement here: bit.ly/45wJnmi #enFuse #drugdelivery #subcu

By allowing mobility during administration, the enFuse empowers patients to live their normal lives while receiving their medication. Learn more about the enFuse on our website: enableinjections.com #enFuse #drugdelivery #subcutaneous #selfadministration #innovativetechnology

The U.S. FDA has approved Apellis Pharmaceuticals’ treatment for complement 3 glomerulopathy (C3G) and primary immune complex-mediated membranoproliferative glomerulonephritis (IC-MPGN), severe and rare kidney diseases, for patients 12 and older: lnkd.in/gjAMgT2T

Why is SC delivery a game-changer for biopharma? Download our whitepaper to discover how wearable technology can simplify drug delivery while also potentially reducing burden on healthcare systems and improving safety & efficacy: lnkd.in/g62UNpXN #drugdelivery #enFuse

We’re proud to announce the enFuse Syringe Transfer System is now registered in the UK! This registration comes after the enFuse recently received CE Mark approval in the EU. We look forward to bringing our technology to patients around the world! #drugdelivery #enFuse

Discover how #subcutaneousdelivery unlocks value and drives sales growth in our white paper published by @FierceBiotech: lnkd.in/g62UNpXN Learn how switching from IV to SC #drugdelivery can be a viable, effective and low risk way to set products apart.